LRRK2 and Parkinson disease: In addition, it provides the opportunity to identify individuals in the general population for studies of the prodromal phase of PD, which so far have required the identification of rare factors associated with high risk (eg, gene carriers of leucine‐rich repeat kinase 2 [LRRK2] mutations), expensive investigations, or active screening of large volunteer cohorts.